AstraZeneca Wins EU Approval for Drug to Rival Plavix
This article is for subscribers only.
AstraZeneca Plc won European approval for a new blood thinner to rival Plavix, the world’s second-biggest-selling drug.
The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of Brilique combined with aspirin to reduce the risk of heart attacks, strokes and death in patients with severe chest pain or earlier heart attacks, the London-based agency said today in a statement. The drug is also known as Brilinta.